Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
3SBio ( (HK:1530) ) has shared an announcement.
3SBio Inc. has announced a cooperation agreement between its subsidiary, Shenyang Sunshine Pharmaceutical Co., Ltd., and Duality Biologics for the commercialization of the HER2 ADC drug DB-1303 in Mainland China, Hong Kong, and Macau. Under the agreement, Shenyang Sunshine will handle commercialization while Duality Biologics will continue clinical development and registration. This partnership aims to strengthen 3SBio’s position in the biopharmaceutical market, though there is no guarantee of successful commercialization.
More about 3SBio
3SBio Inc. operates in the biopharmaceutical industry, specializing in products for cancer and autoimmune diseases. The company focuses on the research and development of innovative therapeutic agents, with a particular emphasis on next-generation ADC (antibody-drug conjugate) drugs.
YTD Price Performance: -5.71%
Average Trading Volume: 313
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.75B
Learn more about 1530 stock on TipRanks’ Stock Analysis page.
